Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Starting treatment news

Show

From To
Rilpivirine better tolerated, less toxic and more durable than efavirenz in first-line ART

Rilpivirine is better tolerated, less toxic and more durable than efavirenz when used as part of a first-line antiretroviral regimen, investigators from Italy report in

Published
28 June 2018
By
Michael Carter
Starting HIV treatment at diagnosis slashes drop out, drug failure rates, China study finds

Patients diagnosed with HIV who started antiretroviral treatment within 30 days had significantly lower rates of dropping out of treatment, and higher rates successful treatment, than those who started later, particularly those who started more than three months after their diagnosis, a study in China has found.

Published
04 June 2018
From
Science Speaks
South Africa: Birth defects fears prompt warnings about new ARV

Despite the public concern globally, very little has been said about the impact of the safety warning about dolutegravir on South Africa, the country with the largest HIV treatment programme in the world. The National Department of Health had already planned to introduce a dolutegravir-based first line regimen to replace the existing regimen, hoping to switch the majority of patients starting from last month.

Published
29 May 2018
From
Health-e
Phase 3 registrational data is not sufficient for roll-out of new ARVs in low- and middle-income countries

Phase 3 randomised trials for drug approval in high-income countries do not provide sufficient evidence to support the widespread use of new antiretrovirals in low- and middle-income countries (LMICs), where the majority of people with HIV live. Key missing evidence is typically for pregnant women, people with HIV/TB coinfection and people who have not had resistance testing before starting ART.

Published
15 May 2018
From
HIV i-Base
State-of-the-art HIV drug could curb HIV transmission, improve survival in India

An HIV treatment regimen already widely used in North America and Europe would likely increase the life expectancy of people living with HIV in India by nearly three years and reduce the number of new HIV infections by 23 percent with minimal impact on the country's HIV/AIDS budget.

Published
01 May 2018
From
Science Daily
Latest DHHS Guidelines for Initial HIV Therapy Now Include 5 Choices — But Really 2 Are Best

With the important caveat that what follows represents my opinion and not that of these or any other guidelines, one could easily argue that there are really two primary choices here, not five.

Published
23 April 2018
From
NEJM Journal Watch
Integrase inhibitors do not raise risk of IRIS in severely immunocompromised people

Use of an integrase inhibitor, which can bring down viral load rapidly, was not associated with an increased risk of immune reconstitution inflammatory syndrome (IRIS) in people

Published
27 March 2018
By
Liz Highleyman
Improving Access to Patient Care & Time to Viral Suppression Using HIV Rapid Entry Programs

The CDC has reported that 44% of individuals who are living with HIV are residing in the southern region of the United States; HIV diagnosis rates are higher in the South than they are for Americans overall.

Published
22 March 2018
From
Contagion Live
Average time from HIV diagnosis to treatment fell to six days in 2016 in San Francisco

The average time from HIV diagnosis to treatment initiation in San Francisco shrank from 35 days to six days between 2013 and 2016 as the city implemented

Published
07 March 2018
By
Keith Alcorn
Same-day treatment start improves retention in care and viral suppression in Lesotho

Starting treatment at home, on the day of diagnosis, proved acceptable in rural Lesotho and resulted in improved linkage to care and viral suppression compared with routine

Published
07 March 2018
By
Keith Alcorn
← First12345...79Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.